Genmab — Februar 2014
-
The development of daratumumab is progressing swiftly and preliminary pivotal data could potentially be presented before year-end. We remain cautious on the market potential for Arzerra, but believe a positive readout of the DLBCL trial could change negative market sentiment. We maintain our Buy recommendation and raise our 12-month target price to DKK325 (DKK275). Our fair value estimate is at DKK377.
-
At nu har Deutsche og Danske løftet kursmål. Kempel (sachsin) har også fornyligt, Jeffries har løftet det
-
Så mon ikke Nordea kommer. Carsten Carnegie må vel også skulle løfte kursmålet siden hans kunde købte 500.000 stk. ?
-
Så misforstod du den
-
Aktieugebrevet: 135 :D:D:D
-
Smider lige MadsSkjerns link herinde også: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2014/02/WC500162067.pdf CHMP skal bruge yderligere oplysninger fra GSK vedrørende ALkylator label
-
spændende - der er fremdrift. Mon ikke det kan være datareadout på fase II studiet med bendamustine, de gerne vil se? http://clinicaltrials.gov/ct2/show/NCT01520922?term=NCT01520922&rank=1
-
vi kan nok konstatere at Danske Bank ikke har nær så meget juice som Deutsche Bank...
-
hvilken indikation tænker du på solsen?
-
er det nhl/cll?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind